<DOC>
	<DOCNO>NCT00796211</DOCNO>
	<brief_summary>This phase 2a single-center , randomize , blind , vehicle-controlled exploratory study ass activity safety CRx-197 subject plaque psoriasis . Approximately 20 male female subject chronic plaque type psoriasis , 18 70 year age , include study . All subject stable psoriatic plaque receive follow treatment separate test field , day four week occlusion : - CRx-197 high dose topical cream ( 0.1 % nortriptyline HCl +0.3 % loratadine ) - CRx-197 low dose topical cream ( 0.1 % nortriptyline HCl + 0.1 % loratadine ) - 0.1 % nortriptyline HCl topical cream - 0.005 % calcipotriol topical cream - Vehicle CRx-197 topical cream ( placebo )</brief_summary>
	<brief_title>A Single-Center Exploratory Study Assess Activity CRx-197-002 Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Nortriptyline</mesh_term>
	<criteria>I01 Subject must voluntarily sign date write informed consent prior study specific procedure I02 Subject must 18 70 year age I03 Subject must chronic plaque psoriasis plaque infiltrate thickness minimum 150 Âµm stable plaque area sufficient five test field untreated control field per plaque I04 Subject must free condition/disease investigator feel interfere interpretation study result . I05 Females childbearing potential age either surgically sterile ( hysterectomy tubal ligation ) , use highly effective medically accept contraceptive regimen . E01 Erythrodermic , guttate pustular psoriasis E02 Cardiac disease , include recent myocardial infarction , degree heart block cardiac arrhythmia valvular heart disease E03 Mania acute delirium epilepsy E04 Narrow angle glaucoma E05 Hyperthyroidism medical history , TSH less LLN , subject receive thyroid medication E06 Diabetes E07 Intolerance lidocaine E08 Severe liver disease [ ALT laboratory value exceed 2.5x ULN ] E09 Known severe kidney disease , acute urinary retention , prostatic hypertrophy post void residual urine laboratory value creatinine exceed 1.5x ULN E10 Significant gastrointestinal disease include limited pyloric stenosis paralytic ileus E11 Inflammatory dermatoses except psoriasis ; bacterial , viral , fungal skin infection ( test plaque ) ; facial rosacea E12 Active varicella , tuberculosis , syphilis postvaccine reaction E13 Autoimmune disease plaque psoriasis ( e.g. , lupus erythematosis ) E14 Known allergic reaction hypersensitivity component study treatment E15 Allergy adhesives template use study E16 UV therapy significant UV exposure four week treatment application E17 History malignancy ( except treat excised basal cell carcinoma ) E18 History drug alcohol abuse ( define Investigator ) E19 Symptoms clinically significant illness four week treatment application may influence outcome study E20 Subject demonstrate hypercalcemia ( calcium great ULN ) evidence Vitamin D toxicity E21 Subject demonstrate hypokalemia ( less LLN )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>CRx-197</keyword>
	<keyword>nortriptyline</keyword>
	<keyword>loratadine</keyword>
	<keyword>CombinatoRx</keyword>
	<keyword>Dermatology</keyword>
	<keyword>Erythema</keyword>
	<keyword>Pruritus</keyword>
</DOC>